Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant

Am J Respir Crit Care Med. 2003 Jun 1;167(11):1562-6. doi: 10.1164/rccm.200207-782OC. Epub 2003 Mar 20.


We performed a phase I/II trial in North America of a recombinant surfactant protein C-based surfactant (Venticute) as treatment for the acute respiratory distress syndrome. Patients were prospectively randomized to receive either standard therapy or standard therapy plus one of two doses of exogenous surfactant given four times over 24 hours. Surfactant administration was well tolerated. No significant treatment benefit was associated with surfactant treatment. Bronchoalveolar lavage of treated patients at 48 hours reflected the presence of exogenous surfactant components, did not show evidence of improved surface tension lowering function, and had interleukin-6 concentrations that were significantly lower than control group values, consistent with an antiinflammatory treatment effect. The presence of exogenous surfactant was not detected in lavage fluid obtained at 120 hours. Future studies might rationally employ larger surfactant doses and a more prolonged dosing schedule.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Bronchoalveolar Lavage Fluid / chemistry
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Surfactant-Associated Protein C / administration & dosage
  • Pulmonary Surfactant-Associated Protein C / therapeutic use*
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use
  • Respiratory Distress Syndrome / drug therapy*


  • Pulmonary Surfactant-Associated Protein C
  • Recombinant Proteins